Table 3 Baseline characteristics for ADDRESS sequence subgroups
Variable | First 2 patients (n = 916) | 3rd and subsequent patients (n = 1,724) | P value |
|---|---|---|---|
Male, number (percentage) | 517 (56.4%) | 999 (57.9%) | 0.46 |
Age in years, mean ± SD | 58.3 ± 16.8 | 58.9 ± 16.6 | 0.36 |
Region, number (percentage) | <0.001 | ||
Europe | 265 (28.9%) | 581 (33.7%) | |
US and Canada | 480 (52.4%) | 681 (39.5%) | |
Other countries | 171 (18.7% | 462 (26.8%) | |
Racial origin, number (percentage) | 0.001 | ||
African descent | 67 (7.3%) | 98 (5.7%) | |
Caucasian | 694 (75.8%) | 1,221 (70.8%) | |
Hispanic | 57 (6.2%) | 144 (8.4%) | |
Asian | 62 (6.7%) | 168 (9.7%) | |
Other | 36 (3.9%) | 93 (5.4%) | |
Number of organ failures, mean ± SD | 1.5 ± 0.7 | 1.4 ± 0.7 | 0.19 |
APACHE II score, mean ± SD | 18.3 ± 5.7 | 18.1 ± 5.9 | 0.22 |
Acute physiology score, mean ± SD | 14.1 ± 5.4 | 13.7 ± 5.4 | 0.07 |
Number of patients with chronic health points (percentage) | 221 (24.1%) | 476 (27.6%) | 0.08 |
Recent surgery, number (percentage) | 321 (35.0%) | 681 (39.5%) | 0.06 |
Time from first organ failure to start of study drug in hours, mean ± SD | 24.1 ± 13.6 | 21.8 ± 13.7 | <0.001 |
Community-acquired infection, number (percentage) | 688 (75.1%) | 1,235 (71.6%) | 0.06 |
Heparin use at baseline, number (percentage) | 504 (55.0%) | 1,047 (60.7%) | 0.005 |